FDA Authorizes New Long-Acting Monoclonal Antibodies (AZD7442 or EVUSHELD) for Pre-Exposure Prevention of COVID-19 in Certain Individuals
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
“MONTREAL , May 23, 2019 /CNW/ – AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, announced today that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices Division’s (DDD) Exceptional Access Program effective May 13, 2019 .iiVENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have no other treatment options. VENCLEXTA is an oral, once-daily medicine.”
Read the full news release here:
Related posts
